Endpoints News 生物医药· Reynald Castaneda·· 27 天前AI 评分35
ESMO26大会:阿斯利康关注Keytruda的Padcev适应症;礼来的ADC药物挑战Elahere;Nubeqa瞄准早期前列腺癌
#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
AI 导读
ESMO26大会预计吸引近4万名代表参会。阿斯利康探讨Keytruda在Padcev适应症领域的潜在布局。礼来ADC药物与Elahere展开竞争,Nubeqa聚焦早期前列腺癌治疗方案。
正文
MADRID — It’s been estimated that almost 40,000 delegates will be attending this year’s ESMO congress over five days in Madrid. And on Saturday, they have …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news